文献速递白血病

低甲基化药物联合维奈克拉一线治疗75岁及以上急性髓系白血病患者的临床结局:来自美国八家学术中心的真实世界数据

Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
PubMed 文献 · Am J Hematol · 2024-02-11

这项多中心回顾性研究纳入美国八家学术中心204例75岁及以上新诊断急性髓系白血病患者,评估低甲基化药物联合维奈克拉一线治疗的真实世界结局。完全缓解/完全缓解伴计数不完全恢复率为64%,中位总生存9.5个月,TP53突变者总生存更差。

要点

  • 204例≥75岁新诊断AML患者接受低甲基化药物联合维奈克拉治疗,CR/CRi率为64%。
  • 中位总生存9.5个月(95%CI 7.85-13.5),低于VIALE-A试验报告的水平。
  • TP53突变患者中位总生存仅2.5个月,NPM1、IDH1、IDH2突变者分别为13.5、18.3、21.1个月。

核心结论

  • 低甲基化药物联合维奈克拉在75岁及以上新诊断急性髓系白血病患者中取得较高缓解率,但中位总生存低于VIALE-A试验报告的水平。
  • 低甲基化药物联合维奈克拉治疗失败后结局不佳,代表亟待满足的临床需求。

研究设计与样本

  • 多中心回顾性研究,纳入美国八家学术中心204例75岁及以上新诊断急性髓系白血病患者,接受低甲基化药物联合维奈克拉一线治疗。

主要发现

  • 64例达到完全缓解(38%),43例达到完全缓解伴计数不完全恢复(26%),CR/CRi率为64%,中位缓解持续时间14.2个月(95%CI 9.43-22.1)。
  • 缓解者中63例复发(59%),复发后中位总生存3.4个月(95%CI 2.4-6.7)。
  • 全人群中位总生存9.5个月(95%CI 7.85-13.5);TP53突变患者中位总生存2.5个月,NPM1、IDH1、IDH2突变患者分别为13.5、18.3、21.1个月。
  • 30天死亡率为9%,60天死亡率为19%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax (VEN) combined with hypomethylating agents (HMAs) is the standard of care for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive chemotherapy. To date, real-world data published on HMAs plus VEN have been either single-center studies or using community-based electronic databases with limited details on mutational landscape, tolerability, and treatment patterns in elderly patients. Therefore, we conducted a multicenter retrospective study to assess the real-world experience of 204 elderly patients (≥75 years) with newly diagnosed AML treated with HMAs plus VEN from eight academic centers in the United States. Overall, 64 patients achieved complete remission (CR; 38%) and 43 CR with incomplete count recovery (CRi; 26%) for a CR/CRi rate of 64%, with a median duration of response of 14.2 months (95% CI: 9.43, 22.1). Among responders, 63 patients relapsed (59%) with median overall survival (OS) after relapse of 3.4 months (95% CI, 2.4, 6.7). Median OS for the entire population was 9.5 months (95% CI, 7.85-13.5), with OS significantly worse among patients with TP53-mutated AML (2.5 months) and improved in patients harboring NPM1, IDH1, and IDH2 mutations (13.5, 18.3, and 21.1 months, respectively). The 30-day and 60-day mortality rates were 9% and 19%, respectively. In conclusion, HMAs plus VEN yielded high response rates in elderly patients with newly diagnosed AML. The median OS was inferior to that reported in the VIALE-A trial. Outcomes are dismal after failure of HMAs plus VEN, representing an area of urgent unmet clinical need.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Abaza Y, Winer ES, Murthy GSG, et al. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. Am J Hematol. 2024. PMID: 38342997. doi:10.1002/ajh.27231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。